Is there any genetic susceptibility to acute promyelocytic leukemia? TO 
THE EDITOR
Acute promyelocytic leukemia (APL) is a distinct subtype of acute myelogenous leukemia (AML) distinguished by a balanced reciprocal translocation between chromosomes 15 and 17 responsible for the molecular rearrangement PML/RAR␣. We read with interest the article by Bolognesi et al 1 concerning data on HLA association in acute promyelocytic leukemia (APL). The authors' data, obtained from 102 patients with newly diagnosed APL provided by the clinical centers belonging to the Italian Cooperative Group GIMEMA, showed a different distribution of alleles between bcr1 and bcr3 patients, and a statistically significant association between HLA-B13 and risk of relapse suggesting a possible identification of patients at high risk of relapse in which more aggressive consolidation therapies should be used. The HLA genes have always played an important part in the search for the hereditary contribution to a disease. Regarding leukemia, pioneering work showed that resistance and susceptibility to murine leukemia virus is mapped to the major histocompatibility complex gene region. In Bolognesi et al's report, 1 the comparison of HLA frequencies in Italian APL patients with those of an ethnically matched control population did not show any difference. Although realized on a smaller series, the frequency of HLA-A, -B, -Cw tested alleles (determined by serological typing) in our recent APL patients was quite similar to that reported in the Italian APL population (Table 1) . Despite an apparent similarity in HLA phenotypes among APL patients and a regular population, a genetic susceptibility to APL may be questionable. Indeed, different features suggest a genetic predisposition or susceptibility to APL related or not to exposure to distinct environmental factors. First of all, relationship between ethnicity and APL has been strongly suggested, APL cases being more frequent in patients from Latino origin. 2 Secondly, population studies have identified possible genetic markers of increased susceptibility to leukemia. 3 In order to illustrate this, we first report the observation of two cases of APL, sharing HLA alleles and bcr1 breakpoint, occurring in the same family, and then discuss the different features sustaining these data.
Case 1, a 35-year-old woman originating from the Christian community of Lebanon, was admitted to our hospital in October 1993. She was first hospitalized in Beirut in August 1993 complaining of bleeding gums and spontaneous bruising. Peripheral blood showed anemia, thrombopenia and white blood cell count of 2.2 × 10 9 /l (7% blast cells). Biological tests showed coagulation disorders with low fibrinogen levels and presence of fibrin degradation products. Bone marrow aspirates confirmed a diagnosis of AML, and the patient received three courses of chemotherapy (one course every 2 weeks) combining daunorubicin (20 mg/day for 4 days) with cytarabine (100 mg/day for 5 days) and etoposide (200 mg/day for 4 days). The patient developed pneumonia. Her WHO performance status progressively declined and her family decided on hospitalization in France. Upon arrival in our institution, peripheral blood showed pancytopenia. Pneumonia was proven to be due to aspergillosis and was treated by amphotericin B and then itraconazole. The bone marrow was markedly hypocellular, but had typical findings of APL with hypergranular blasts, many with multiple Auer rods. Cytogenetic according to our schedule combining oral ATRA therapy (45 mg/m 2 /day) from day 1 to complete remission (CR) achievement followed by EMA-timed sequential chemotherapy. While pneumonia was improving under itraconazole, neurological complications occurred on day 41 of ATRA therapy. The patient abruptly presented with headache and seizures without localized neurologic deficit. Cranial CT scan showed a right mass, in frontal and parietal areas, suggestive of subdural hematoma. Neurosurgical excision was successfully performed. CR was achieved by day 77. Then the patient received EMA-timed sequential chemotherapy combining mitoxantrone 12 mg/m 2 /day for 3 days, etoposide 200 mg/m 2 /day for 3 days, and cytarabine 500 mg/m 2 /day for two sequences of 3 days. Case 1 had three sibling donors (Table 2) . From HLA phenotypes, parents' haplotypes could be deduced showing a haplotype in common strongly suggesting a notion of consanguinity between them. Despite the presence of suitable familial donors, she received a second course of EMA chemotherapy as consolidation therapy. The patient is currently alive more than 6 years after CR achievement. She is still in cytological CR and has no detectable PML/RAR␣ rearrangement by RT-PCR determinations.
Case 2, a 56-year-old woman, was first admitted to our hospital in February 1995. She was related to case 1 (case 1's father's brother's wife), and came from the same village in Lebanon. Interrogation also revealed that she was case 1's mother's cousin (two generations). She was first hospitalized in Lebanon in January 1995 for AML and was treated by daunorubicin (40 mg/day for 2 days) and cytarabine (150 mg/day for 6 days). At arrival in our institution, peripheral blood showed anemia, thrombocytopenia and white blood cell count of 7 × 10 9 /l (63% blasts with abundance of Auer bodies). LDH level was at 1130 UI/l. Bone marrow aspirates showed an infiltration by leukemic cells with t(15;17) confirming the diagnosis of typical APL. Molecular biology showed PML/RAR␣ rearrangement with bcr1 breakpoint. HLA phenotype was A68 (or 69) A29 B7 B51 DR11 DR52 DQ7. Treatment was started according to the same schedule as in case 1. ATRA therapy was marked by side-effects: bilateral myodesopsia with beginning of venous thrombosis involving the left eye, bone pain and arthralgias, signs of pulmonary embolism. Despite those complications, ATRA was continued until CR achievement obtained by day 32. Then she received two courses of EMA-timed sequential chemotherapy. Aplasia following the second course of chemotherapy was marked by pulmonary aspergillosis that was successfully treated by amphotericin B then itraconazole. The patient is currently alive more than 5 years after CR achievement. She is still in cytological and molecular CR.
First of all, this observation described the occurrence of the same leukemia subtype (representing generally about 10% of all AML) in members of the same family. The two patients were related by case 1's mother who was case 2's cousin. Furthermore, they belonged to the same Lebanese community in which consanguinity seems relatively frequent as suggested by the expression of similar HLA alleles in the two patients and by the expression of a similar haplotype in case 1's parents. The two patients were also living in the same environment and leukemia occurred with a less than 2-year interval. Familial leukemia may be indicative of rare genes restricted to a given family, or it may be the outcome of exposure to a common environmental agent. Those two possibilities are not mutually exclusive. Heredity is of importance in some disorders that predispose individuals to leukemia such as ataxia-telangiectasia or Fanconi's anemia. Although findings of discordant leukemia in adolescent and adult twins have been described, convincing evidence for the origin of monozygotic A1  21%  28%  B7  14%  15%  Cw2  38%  12%  A2  49%  43%  B8  19%  16%  Cw3  23%  20%  A3  23%  23%  B12  2%  -Cw4  62%  17%  A10  2%  -B13  7%  4%  A11  5%  9%  B14  9%  9%  A23  7%  2%  B17  2%  -A24  16%  20%  B18  9%  9%  A25  7%  2%  B27  12%  6%  A26  9%  9%  B35  26%  14%  A28   a   21%  12%  B38  2%  4%  A29  9%  11%  B39  12%  5%  A30  9%  8%  B41  7%  3%  A32  5%  14%  B44  21%  25%  A34  2%  1%  B45  2%  3%  B49  5%  5%  B50  2%  4%  B51  21%  12%  B53  2%  3%  B58  5%  3%  B60  5%  7%  B62  5%  -B70 2% -
The ethnic origins of APL patients and of healthy controls were similar. Both comprised individuals from different origins living in our region including subjects from the Mediterranean area. Reported frequencies for the various alleles refer to the number of individuals carrying a given allele (phenotypic frequency). a A68 and A69. leukemia as a single event has been obtained by chromosome analysis of monozygotic twin leukemias, which shows that the same marker occurs in both twins. 4 Hereditary susceptibility was clearly evident in studies investigating the role of carcinogens in animals. Leukemia develops as the result of one or more somatic mutations as nonrandom chromosome rearrangements in hemopoietic progenitor cell. Indeed, it may occur as a consequence of heritable characteristics that favor leukemogenesis such as defective responses to environmental carcinogens and an inability to detoxify mutagenic chemicals or to repair damaged DNA. Susceptibility genes may be alleles that increase disease risk by being less efficient in protecting against a leukemia-causing agent.
Secondly, our observation points to a possible predisposition for APL in some communities. Certain populations may be more prone to chromosomal breakage at a site involved in the t(15;17). Indeed, previous studies suggest a genetic predisposition toward APL in the Latino population, accounting for one third of AML. 2 The frequency seems to be higher in Southern Europe compared with North and Central Europe. Several small series from different countries have previously noted a higher-than-expected frequency of APL in pediatric AML patients. 5 However, certain similarities in the prevalence of APL have been found among populations with very different genetic composition. This could also be explain by environmental factors, with Leukemia or without a genetic predisposition. It is widely accepted that environmental factors play an important part in the etiology of leukemia. Differences in worldwide incidence rates due to socioeconomic, lifestyle and localized clusters in relation to environmental hazards have generally been interpreted as evidence of this. Exposure to carcinogens could play a role since the association of APL with exposure to certain chemicals or the development of APL after a prior cancer treatment is now well known. 6 Combination with particular HLA phenotypes could be suspected. Previous studies concluded that there was no evidence of an HLA-linked leukemia susceptibility gene in AML, while other reports found a significant association with Cw4 or a decrease in A19, or claimed an increase in intra-HLA recombination in the families of leukemia patients. 3 Bolognesi et al's series, 1 as well as ours, did not show significant differences in HLA phenotypes among APL patients and an ethnically matched control population. However, the percentage of our patients expressing HLA-Cw4 was higher than expected (Table 3) . Small communities were genetically isolated. Our case reports question the role of consanguinity. Indeed, there is a strong suspicion of consanguinity among case 1's parents who shared a haplotype. Although consanguinity in leukemia was infrequent, increased frequency of leukemia in isolated communities has been previously reported. 7 Consanguinity could favor emergence of HLA-linked leukemia susceptibility alleles. Our two patients shared DR1  11%  21%  DQ1  18%  -DR2  17%  -DQ2  33%  28%  DR3  23%  18%  DQ3  15%  2%  DR4  20%  24%  DQ4  3%  4%  DR7  20%  15%  DQ5  18%  34%  DR8  9%  7%  DQ6  24%  36%  DR11  29%  27%  DQ7  33%  45%  DR13  17%  26%  DQ8  3%  18%  DR14  6%  9%  DR15  14%  17%  DR52  40%  -DR53 14% -
The ethnic origins of APL patients and of healthy controls were similar. Both comprised individuals from different origins living in our region including subjects from Mediterranean area. Reported frequencies for the various alleles refer to the number of individuals carrying a given allele (phenotypic frequency).
A68 (or 69) DR11 DR52 DQ7 alleles. This HLA phenotype was only found in one other patient of our APL series, while the combination DR11 DR52 DQ7 was found in 17% of our APL patients. Larger epidemiological investigations are warranted as additional research modes to investigate the etiology, biology, and then optimal treatment of APL. HLA studies must be reconsidered and performed on larger series. Knowledge about the risks of leukemia will be important in the future for genetic counseling, in assessing environmental risks, and in deploying preventive measures.
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